As a minimally invasive technology for detecting signs of cancer and other diseases, the liquid biopsy can sidestep stressful, costly surgical procedures. QIAGEN’s liquid biopsy solutions enable you to sensitively, specifically and quickly analyze circulating free nucleic acids (cfDNA), exosomes and circulating tumor cells (CTCs) from blood and other biofluids. This means you can find and study elusive low-abundance DNA fragments, evaluate valuable biomarkers from cellular vesicles, or even analyze a whole genome or transcriptome from a single tumor cell.
About the speaker
Date of recording:Thursday, July 23, 2020
Duration:1 hour
Categories
Webinar
Oncology
Immune Response
Liquid Biopsy
X
Cookies help us improve your website experience.
By using our website, you agree to our use of cookies.
Confirm